Roth Capital Rates Exagen (XGN) buy, $8 Price Target

Roth Capital reaffirms its 'buy' rating for Exagen Inc. with an $8 target, a 74.67% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 7:02 AM EDT · Updated Jun 29, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Roth Capital rated Exagen Inc. ($XGN) "buy" with a $8 price target on June 25, 2026.

Since the rating, $XGN is down 2.2% after 1 week, down 5.2% after 1 month and up 66.4% to date (from the $4.64 close on Jun 25, 2026).

XGN Exagen Inc.

$7.72 +27.81% year to date

Daily close · Oct 16, 2026

Key Points

Roth Capital reiterated its 'buy' rating on Exagen Inc. (XGN) with a price target of $8.00 on June 25, 2026.
Roth Capital's $8 price target implies 74.67% upside from Exagen Inc.'s ($XGN) current $4.58 share price.
Exagen Inc. shares traded near $4.52 on Thursday, with a market cap of approximately $107 million.
Peers like Wexford Capital LP and Nano Cap New Millennium Growth Fund L.P. have significantly adjusted their positions in Exagen.

Get $XGN trade alerts by text

We text you when insiders, Congress or big funds trade $XGN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Exagen Inc. alert may contain errors. Disclosures

Roth Capital reaffirmed its 'buy' rating for Exagen Inc. (NasdaqGM: XGN) on June 25, 2026. Analyst Max Masucci set a price target of $8.00, unchanged from prior assessments. Shares of Exagen traded near $4.52 on Thursday.

Analyst rating track record

Roth Capital vs. the S&P 500

YTD return +12.58% hypothetical

All-time return +14.57% S&P 500 +12.92%

vs. S&P 500 +1.65% ahead of the index

Hypothetical returns from Roth Capital's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Exagen Inc.

Several institutional investors have adjusted their holdings in Exagen Inc. Wexford Capital LP increased its stake by 326,077 shares, ending with 792,855 shares valued at about $2.38 million, a 69.9% increase. Nano Cap New Millennium Growth Fund L.P. expanded its position by 335,000 shares, now holding 585,000 shares worth approximately $1.76 million, reflecting a 134% increase. Meanwhile, Vanguard Capital Management LLC opened a new position with 678,652 shares valued at $2.04 million. On the other hand, Balyasny Asset Management L.P. reduced its holdings by 122,555 shares, leaving it with 796,632 shares worth around $2.39 million, a 13.3% decrease.

Exagen Inc. Stock Down 45.5%

Exagen Inc. shares traded near $4.52 on Thursday. The company has a market cap of about $107 million and a beta of 2.017, indicating a higher volatility compared to the market. The stock has seen a 52-week low of $2.59 and a high of $12.23. Its 50-day moving average is $3.73, and the 200-day moving average is $6.09. Exagen's current ratio stands at 3.469, with a quick ratio of 2.968 and a debt-to-equity ratio of 188.096.

12-month forecast

$XGN price target

Exagen Inc. daily closes and this analyst's $8 target. Not advice.

Recent Earnings

In its most recent earnings report, Exagen Inc. posted revenue of $68.38 million, marking a growth of 11.7%. However, the company reported a net margin of -29.49% and a return on equity of -193.58%, indicating challenges in profitability. The company is set to announce its next earnings on August 4, 2026.

Insider Buying and Selling at Exagen Inc.

Insider activity at Exagen Inc. shows several purchases. On June 9, 2026, insiders Frank Stokes, Scott Kahn, and Chas McKhann each acquired 37,500 shares. Earlier in March, CEO John Aballi bought 100,000 shares at $3.16 per share and an additional 150,000 shares, though the transaction value wasn't disclosed. CFO Jeffrey Black also purchased 75,000 shares at the same price.

Analysts Set New Price Targets

On June 25, 2026, Roth Capital reiterated its 'buy' rating for Exagen Inc. with an $8.00 price target. Previously, BTIG maintained its 'buy' rating with an $8.00 target on May 12, 2026. Canaccord Genuity also maintained its 'buy' rating with a target of $8.00 on April 20, 2026. The consensus target price is $8.67, based on six analyst opinions.

About Exagen Inc.

Exagen Inc., headquartered in Vista, California, designs and sells diagnostic tests under the AVISE brand. The company focuses on helping healthcare providers diagnose and monitor autoimmune diseases like lupus and rheumatoid arthritis. Its flagship product, AVISE CTD, aids in diagnosing connective tissue diseases. Exagen also collaborates with Allegheny Health Network to develop T-Cell biomarkers. The company, led by CEO John Aballi, employs 216 people.

Bottom Line

Roth Capital's reaffirmation of a 'buy' rating for Exagen Inc. highlights continued confidence in the company's potential. Exagen specializes in diagnostic solutions for autoimmune diseases, a growing area in healthcare. Investors should note that 13F filings and analyst ratings are backward-looking and may not represent current positions or recommendations.